Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Use of Oncotype DX in Women with Node-Positive Breast Cancer.

Ishibe N, Schully S, Freedman A, Ramsey SD.

PLoS Curr. 2011 Jul 21;3:RRN1249. doi: 10.1371/currents.RRN1249.

2.
3.

Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.

Genet Med. 2016 Aug;18(8):770-9. doi: 10.1038/gim.2015.173. Epub 2015 Dec 17.

PMID:
26681310
4.

Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.

Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY.

Breast J. 2013 May-Jun;19(3):269-75. doi: 10.1111/tbj.12099.

PMID:
23614365
5.

Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.

Yang M, Rajan S, Issa AM.

Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22.

6.

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.

McVeigh TP, Kerin MJ.

Breast Cancer (Dove Med Press). 2017 May 29;9:393-400. doi: 10.2147/BCTT.S109847. eCollection 2017. Review.

7.

Impact of oncotype DX recurrence score in the management of breast cancer cases.

Nguyen MT, Stessin A, Nagar H, D'Alfonso TM, Chen Z, Cigler T, Hayes MK, Shin SJ.

Clin Breast Cancer. 2014 Jun;14(3):182-90. doi: 10.1016/j.clbc.2013.12.002. Epub 2013 Dec 27.

PMID:
24486121
8.

Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.

Cheung PS, Tong AC, Leung RC, Kwan WH, Yau TC.

Hong Kong Med J. 2014 Oct;20(5):401-6. doi: 10.12809/hkmj134140. Epub 2014 Jun 20.

9.

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.

Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J.

Value Health. 2010 Jun-Jul;13(4):381-7. doi: 10.1111/j.1524-4733.2010.00724.x. Epub 2010 Apr 15.

10.
11.

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI.

Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021.

PMID:
18809056
12.

The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.

McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, Kerin MJ.

Eur J Cancer. 2014 Nov;50(16):2763-70. doi: 10.1016/j.ejca.2014.08.002. Epub 2014 Sep 15.

13.

Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.

Tan AC, Li BT, Nahar K, Danieletto S, Fong ES, Currer T, Parasyn A, Middleton P, Wong H, Smart D, Rutovitz JJ, McCloud P, Hughes TM, Marx GM.

Asia Pac J Clin Oncol. 2017 Sep 29. doi: 10.1111/ajco.12779. [Epub ahead of print]

PMID:
28960862
14.

Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. Review.

PMID:
18159035
15.

A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.

Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, Rolles M, Moe M, Khawaja S, Sharaiha Y, Brinkworth E, Whelan S, Jones S, Bennett H, Phillips CJ.

Br J Cancer. 2013 Jun 11;108(11):2250-8. doi: 10.1038/bjc.2013.207. Epub 2013 May 21.

16.

Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.

Zhu X, Dent S, Paquet L, Zhang T, Graham N, Song X.

Eur J Cancer. 2014 Oct;50(15):2544-9. doi: 10.1016/j.ejca.2014.07.010. Epub 2014 Aug 13.

PMID:
25129366
17.

The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.

de Boer RH, Baker C, Speakman D, Chao CY, Yoshizawa C, Mann GB.

Med J Aust. 2013 Aug 5;199(3):205-8.

PMID:
23909545
18.

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH Jr, Panasci LC.

Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4.

19.

An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.

Felts JL, Zhu J, Han B, Smith SJ, Truica CI.

Breast J. 2017 Jan 18. doi: 10.1111/tbj.12751. [Epub ahead of print]

PMID:
28097781
20.

Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.

Gradishar WJ, Hansen NM, Susnik B.

Clin Adv Hematol Oncol. 2009 Apr;7(4):1-7.

PMID:
19536946

Supplemental Content

Support Center